In last trading session, Capricor Therapeutics Inc (NASDAQ:CAPR) saw 2.25 million shares changing hands with its beta currently measuring 0.66. Company’s recent per share price level of $13.15 trading at -$0.74 or -5.33% at ring of the bell on the day assigns it a market valuation of $600.65M. That closing price of CAPR’s stock is at a discount of -77.95% from its 52-week high price of $23.40 and is indicating a premium of 73.23% from its 52-week low price of $3.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.3 million shares which gives us an average trading volume of 1.32 million if we extend that period to 3-months.

For Capricor Therapeutics Inc (CAPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.32 in the current quarter.

Capricor Therapeutics Inc (NASDAQ:CAPR) trade information

Upright in the red during last session for losing -5.33%, in the last five days CAPR remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $13.15 price level, adding 9.0% to its value on the day. Capricor Therapeutics Inc’s shares saw a change of -4.71% in year-to-date performance and have moved 33.91% in past 5-day. Capricor Therapeutics Inc (NASDAQ:CAPR) showed a performance of -0.98% in past 30-days. Number of shares sold short was 9.3 million shares which calculate 5.54 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 12.33% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 21.5. It follows that stock’s current price would jump 23.95% in reaching the projected high whereas dropping to the targeted low would mean a gain of 23.95% for stock’s current value.

Capricor Therapeutics Inc (CAPR) estimates and forecasts

This year revenue growth is estimated to rise 184.04% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.16M for the same. And 6 analysts are in estimates of company making revenue of 4.05M in the next quarter. Company posted 4.91M and 3.97M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.01% during past 5 years.

Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders

Insiders are in possession of 16.81% of company’s total shares while institution are holding 38.19 percent of that, with stock having share float percentage of 45.91%. Investors also watch the number of corporate investors in a company very closely, which is 38.19% institutions for Capricor Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CAPR for having 1.63 million shares of worth $7.77 million. And as of 2024-06-30, it was holding 5.1145 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.55 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.8645 of outstanding shares, having a total worth of $7.39 million.

On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 1.34 shares of worth $17.64 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 1.13 shares on Dec 31, 2024 , making its stake of worth around $14.89 million in the company or a holder of 2.48% of company’s stock.